The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer
Altered energy metabolism is one of the hallmarks of tumorigenesis and essential for
fulfilling the high demand for metabolic energy in a tumor through accelerating glycolysis …
fulfilling the high demand for metabolic energy in a tumor through accelerating glycolysis …
Molecular classification of hormone receptor-positive HER2-negative breast cancer
X Jin, YF Zhou, D Ma, S Zhao, CJ Lin, Y Xiao, T Fu… - Nature …, 2023 - nature.com
Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …
Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy
Z Chen, X Wang, N Zhao, H Chen… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Introduction Tumors pose a significant global economic and health burden, with
conventional cancer treatments lacking tumor specificity, leading to limited efficiency and …
conventional cancer treatments lacking tumor specificity, leading to limited efficiency and …
Platinum (IV) complexes as inhibitors of STAT3 and regulators of the tumor microenvironment to control breast cancer
L Cai, Y Wang, H Chen, Y Tan, T Yang… - Journal of Medicinal …, 2023 - ACS Publications
Interplay between breast cancer (BC) cells and the tumor microenvironment (TME)
influences the outcome of cancer treatment. Aberrant activation of signal transducer and …
influences the outcome of cancer treatment. Aberrant activation of signal transducer and …
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2-advanced breast cancer
EP Hamilton, C Ma, M De Laurentiis, H Iwata… - Future …, 2024 - Taylor & Francis
Abstract Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3
ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent …
ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent …
CDK7 in breast cancer: mechanisms of action and therapeutic potential
Y Gong, H Li - Cell Communication and Signaling, 2024 - Springer
Abstract Cyclin-dependent kinase 7 (CDK7) serves as a pivotal regulator in orchestrating
cellular cycle dynamics and gene transcriptional activity. Elevated expression levels of …
cellular cycle dynamics and gene transcriptional activity. Elevated expression levels of …
M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1
L Zhang, S Gu, L Wang, L Zhao, T Li, X Zhao… - … -Research and Practice, 2024 - Elsevier
Background M2 macrophages are known to play a significant role in the progression of triple-
negative breast cancer (TNBC) by creating an immunosuppressive microenvironment. The …
negative breast cancer (TNBC) by creating an immunosuppressive microenvironment. The …
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
J Wang, B Li, M Luo, J Huang, K Zhang… - … and Targeted Therapy, 2024 - nature.com
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation
M Hua, F Xiong, S Chong, Z Zhang, Q Liu, J Hou… - Cancer Treatment …, 2024 - Elsevier
Background Recently, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have emerged as a
novel treatment strategy for breast cancer. However, increasing reports of CDK4/6i …
novel treatment strategy for breast cancer. However, increasing reports of CDK4/6i …
An oral bioactive chitosan-decorated doxorubicin nanoparticles/bacteria bioconjugates enhance chemotherapy efficacy in an in-situ breast cancer model
J Li, Q Wen, J Dai, B Wang, Y Lu, Z Wu, Y Fan… - International Journal of …, 2024 - Elsevier
Breast cancer is the second leading cause of cancer-related deaths among women
worldwide. Despite significant advancements in chemotherapy, its effectiveness is often …
worldwide. Despite significant advancements in chemotherapy, its effectiveness is often …